ADVERTISEMENT
2 /3 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Gene Therapy

Roche pays $1.15 billion for Sarepta gene therapy

by Ryan Cross
January 3, 2020 | APPEARED IN VOLUME 98, ISSUE 1

Roche is expanding its reach in gene therapy with a $1.15 billion deal to commercialize outside the US a Sarepta Therapeutics gene therapy for Duchenne muscular dystrophy. In December, Roche completed its delayed $4.8 billion acquisition of Spark Therapeutics, a gene therapy firm focused on eye and blood diseases. Sarepta’s therapy, which uses a virus to deliver a microdystrophin gene, originally came from Nationwide Children’s Hospital. The firm is recruiting for a Phase II clinical trial.

X

Article:

This article has been sent to the following recipient:

Leave A Comment

*Required to comment